Dr. Holick has made numerous contributions to the field of the biochemistry, physiology, metabolism, and photobiology of vitamin D for human nutrition. Dr. Holick has established global recommendations advising sunlight exposure as an integral source of vitamin D. He has helped increase awareness in the pediatric and medical communities regarding vitamin D deficiency pandemic, and its role in causing not only metabolic bone disease, and osteoporosis in adults, but increasing risk of children and adults developing preeclampsia, common deadly cancers, schizophrenia, infectious diseases including TB and influenza, autoimmune diseases including type 1 diabetes and multiple sclerosis, type 2 diabetes, stroke and heart disease.
Dr. Holick is a Diplomate of the American Board of Internal Medicine, a Fellow of the American College of Nutrition, and a member of the American Association of Physicians. He is the recipient of numerous awards and honors, including the General Clinical Research Centers Program Award for Excellence in Clinical Research from NIH, American College of Nutrition’s Communication Media Award, Best Docs in America, the Linus Pauling Functional Medicine Award from the Institute for Functional Medicine and the Linus Pauling Prize for Human Nutrition. Dr. Holick serves on a number of national committees and editorial boards and has organized and/or co-chaired several international symposia. He served as the chair for the Endocrine Society’s Practice Guidelines on Vitamin D. He has authored more than 400 peer-reviewed publications, and written more than 200 review articles, as well as numerous book chapters. He has acted as editor and/or co-editor on 13 books, and has written The UV Advantage in 2004 and The Vitamin D Solution in 2010 and helped develop the dminder.info app.
- Professor, Physiology & Biophysics, Boston University School of Medicine
- Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
- Graduate Faculty (Primary Mentor of Grad Students), Boston University School of Medicine, Graduate Medical Sciences
- Director, General Clinical Research Unit, Boston University Medical Campus
- Director, Bone Health Care Clinic, Boston Medical Center
- Director of the Vitamin D, Skin and Bone Research Laboratory, Endocrinology, Diabetes, Nutrition & Weight Management, Medicine, Boston University School of Medicine
- University of Wisconsin-Madison, MD
- University of Wisconsin-Madison, PhD
- University of Wisconsin-Madison, MS
- Seton Hall University, BS
- Published on 5/14/2022
Maghbooli Z, Mozaffari S, Dehghani Y, Rezaei Amirkiasar P, Malekhosseini AA, Rezanejad M, Holick MF. The lower basal metabolic rate is associated with increased risk of osteosarcopenia in postmenopausal women. BMC Womens Health. 2022 May 14; 22(1):171. PMID: 35568898.
- Published on 4/10/2022
Amon U, Yaguboglu R, Ennis M, Holick MF, Amon J. Safety Data in Patients with Autoimmune Diseases during Treatment with High Doses of Vitamin D3 According to the "Coimbra Protocol". Nutrients. 2022 Apr 10; 14(8). PMID: 35458137.
- Published on 3/7/2022
Menéndez SG, Martín Giménez VM, Holick MF, Barrantes FJ, Manucha W. COVID-19 and neurological sequelae: Vitamin D as a possible neuroprotective and/or neuroreparative agent. Life Sci. 2022 May 15; 297:120464. PMID: 35271880.
- Published on 2/24/2022
Holick MF. The CO-VID D-Lemma: A Call for Action. Nutrients. 2022 Feb 24; 14(5). PMID: 35267938.
- Published on 1/4/2022
Bae JH, Choe HJ, Holick MF, Lim S. Association of vitamin D status with COVID-19 and its severity : Vitamin D and COVID-19: a narrative review. Rev Endocr Metab Disord. 2022 06; 23(3):579-599. PMID: 34982377.
- Published on 10/15/2021
Charoenngam N, Holick MF. Marked Underestimation of Serum 25-hydroxyvitamin D Concentrations by The Abbot Architect Chemiluminescent Microparticle Immunoassay in Patients Receiving Vitamin D2 Supplementation. Endocr Pract. 2022 Jan; 28(1):122-123. PMID: 34656785.
- Published on 10/13/2021
Maghbooli Z, Sahraian MA, Jamalimoghadamsiahkali S, Asadi A, Zarei A, Zendehdel A, Varzandi T, Mohammadnabi S, Alijani N, Karimi M, Shirvani A, Holick MF. Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial. Endocr Pract. 2021 Dec; 27(12):1242-1251. PMID: 34653608.
- Published on 10/6/2021
Martín Giménez VM, Lahore H, Ferder L, Holick MF, Manucha W. The little-explored therapeutic potential of nanoformulations of 1,25-dihydroxyvitamin D3 and its active analogs in prevalent inflammatory and oxidative disorders. Nanomedicine (Lond). 2021 11; 16(26):2327-2330. PMID: 34610750.
- Published on 9/1/2021
Charoenngam N, Kalajian TA, Shirvani A, Yoon GH, Desai S, McCarthy A, Apovian CM, Holick MF. A pilot-randomized, double-blind crossover trial to evaluate the pharmacokinetics of orally administered 25-hydroxyvitamin D3 and vitamin D3 in healthy adults with differing BMI and in adults with intestinal malabsorption. Am J Clin Nutr. 2021 09 01; 114(3):1189-1199. PMID: 34008842.
- Published on 9/1/2021
Charoenngam N, Kalajian TA, Shirvani A, Yoon GH, Desai S, McCarthy A, Apovian CM, Holick MF. Reply to S Minisola et al. Am J Clin Nutr. 2021 09 01; 114(3):1252-1253. PMID: 34467971.
View 608 more publications: View full profile at BUMC